The lawsuit filed against the manufacturer of Xarelto (Janssen Pharmaceutical) and the co-marketer (Bayer Healthcare) states these companies failed to warn patients and physicians of the increased risks of fatal internal bleeding when using Xarelto. Plaintiffs attorneys argue that if these companies had warned of the risks, then patients would have been prescribed the drug warfarin, a medication in which internal bleeding can be treated with dosages of Vitamin K.
Why is Xarelto Utilized
Xarelto is an anticoagulant (blood thinner) manufactured by Janssen Pharmaceutical that has been widely prescribed to prevent blood clots in patients suffering from atrial fibrillation (irregular heartbeat); deep vein thrombosis (blood clots deep within the body); pulmonary embolism (blood clots in the lungs); stroke; and patients who have recently undergone a knee or hip replacement surgery. It generally is prescribed as an alternative to warfarin (Coumadin), a blood thinner that began to be used in 1954.
Side Effects of Xarelto
The most serious potential side effect, complication and risk caused by Xarelto is severe internal bleeding that can result in death. Currently, there is no known cure to reverse the type of internal bleeding caused by Xarelto.
Other potential injuries caused by Xarelto include infection associated with hip or knee replacement surgery; decreased hemoglobin (a substance that carries oxygen in red blood cells); bleeding in the brain; hematoma (a mass in the blood); peripheral edema (swelling of the lower limbs); and dyspnea (difficulty breathing).
If you are currently taking Xarelto, it is important to do your best to avoid activities that could result in you getting cut, bruised, or suffering external or internal bleeding. If you do sustain these types of injuries (and especially if you experience swelling, bruising, bleeding, vision changes, confusion, weakness, dizziness or severe headaches), it's important to immediately contact and inform your doctor. Additionally, make sure to inform all your doctors and dentists of your use of Xarelto, and especially before having any medical/dental procedures or surgeries, or if you have uncontrolled high blood pressure, abnormal kidney function, take medication associated with bleeding (e.g. aspirin), or abuse alcohol.
Also, if you are, or become, pregnant make sure your doctor is clearly told.
Xarelto Lawsuit Videos
FDA and Scientific Studies Regarding Xarelto
Perspective on Drug HypersensitivitySince 2012 QuarterWatch has reported prominent signals for the bleeding risks of three anticoagulant drugs, dabigatran (PRADAXA), rivaroxaban (XARELTO), and warfarin (COUMADIN). The concerns arose in a setting of a race to market replacements for warfarin, a generic drug first approved in 1956. Both dabigatran and rivaroxaban were marketed as providing the same or slightly better results than warfarin in preventing strokes and other blood clot-related events, but were easier to use because weekly or monthly blood level tests were not required or available. Dabigatran was first to win approval in October 2010 for use in non-valvular atrial fibrillation, followed by rivaroxaban for this population, in November 2011. In December 2012, the FDA approved an additional contender, apixaban (ELIQUIS), but no data are yet available for review. To read more, click Institute for Safe Medication Practices
Rivaroxaban (XARELTO) Safety ProfileIn the first quarter of 2012 we identified 356 reports of serious, disabling, or fatal injury in which rivaroxaban was the primary suspect drug. The report total more than doubled from the previous quarter total of 128 cases. The unexpected result was that unlike other anticoagulants (warfarin, dabigatran, and enoxaparin) the primary reported event was not the well-understood risk of hemorrhage. Instead, the largest identifiable category was serious blood-clot-related injury—most frequently pulmonary embolism—the very events rivaroxaban is intended to prevent. To read more, click Institute for Safe Medication Practices
Xarelto Recall Information
As of this time, there has not been a recall of Xarelto related to internal bleeding. However, the investigation into this drug, from a legal standpoint, is still at its early stages. It often takes many years; tens of thousands of hours of attorney time; and the expense of many millions of dollars before all the facts come out that will lead to a recall.
Xarelto Lawsuit NewsDocument Claims Drug Makers Deceived a Top Medical Journal:
It is a startling accusation, buried in a footnote in a legal briefing filed recently in federal court: Did two major pharmaceutical companies, in an effort to protect their blockbuster drug, mislead editors at one of the world’s most prestigious medical journals? Lawyers for patients suing Johnson & Johnson and Bayer over the safety of the anticlotting drug Xarelto say the answer is yes, claiming that a letter published in The New England Journal of Medicine and written primarily by researchers at Duke University left out critical laboratory data. They claim the companies were complicit by staying silent, helping deceive the editors while the companies were in the midst of providing the very same data to regulators in the United States and Europe. To read more, click New York TimesTrial for Bayer drug Xarelto under scrutiny over defective device:
European and U.S. drug regulators are looking into whether a defective blood clotting test device affected a trial involving Bayer's top-selling anti-clotting drug Xarelto, hitting the German drugmaker's shares. The study compared Xarelto, also known as rivaroxaban, with older drug warfarin for preventing strokes in patients with a type of irregular heartbeat common among the elderly. "Due to the defect it is now thought that the INR (international normalised ratio) device may have impacted the clotting results in some patients in the warfarin group," the European Medicines Agency (EMA) said, adding it would publish results of its investigation when complete. To read more, click Reuters
Data from the key phase III trial that allowed the oral anticoagulant rivaroxaban on to the market for the prevention of ischemic stroke in non-valvular atrial fibrillation is being reanalyzed because of the use of a faulty device. The European Medicines Agency has also told The BMJ that it has launched an investigation into the trial. To read more, click British Medical JournalNew anticoagulant drugs provide stroke prevention with dose of danger:
Xarelto is one of four anticoagulants approved since 2010 that make up a class of lucrative new drugs marketed as more convenient than warfarin. While warfarin has a blood thinning action that can be halted in a bleeding emergency, none of the newer drugs has an approved antidote. When Glatz developed gastrointestinal bleeding, a few months after she started taking Xarelto, doctors could not make it stop. She died March 23, 2012, at a Kenosha hospital. To read more, click Journal SentinelXarelto: “One Size Does NOT Fit All”:
A big selling point for the “new generation” anticoagulants was its simplicity: whereas the old treatment, warfarin, had many potential interactions, requiring frequent (and expensive) patient monitoring, the new treatments had relatively few interactions. Warfarin patients must also keep track of their INR. There were two issues in which the drug companies responsible for the new anticoagulant Xarelto went wrong. First of all, once a patient starts hemorrhaging, there is virtually no way to stop it. The second issue is related to the first. In its market promotions, Bayer stated that when it came to dosage, Xarelto offered a “one size fits all” approach. To read more, click Levin Law NewsDamning Evidence Revealed in Xarelto Lawsuit: Were Bayer and Janssen Corrupt, or Lazy?:
In early January of 2012, William Packard’s physician prescribed a new anti-coagulant for the treatment of his atrial fibrillation (AT), a condition characterized by irregular heartbeat and palpitations. Patients suffering from AT run an increased risk for heart failure as well as stroke. Mr. Packard’s doctor thought the new medication would be more effective than the old treatment, because there were fewer interactions and the patient wouldn’t have to undergo nearly as much monitoring. To read more, click Ring of Fire Radio NewsCourt Appoints Lead Attorneys for Xarelto Injury Lawsuit:
The Court presiding over all the consolidated federal lawsuits related to Xarelto bleeding injuries has appointed lead counsel for the Plaintiffs’ Steering Committee. In Pretrial Order #7 signed by the Hon. Eldon E. Fallon, both Brian H. Barr of the Levin Papantonio law firm and Andy D. Birchfield of the Beasley Allen law firm were appointed as co-lead counsel to head a core group of twelve law firms that will litigate the case on behalf of injured plaintiffs. Cases involving bleeding injuries suffered by patients taking the Xarelto blood thinning medication filed against Johnson & Johnson and Bayer were previously consolidated before Judge Fallon into one federal action known as MDL 2592. Defendants include three German-based Bayer entities – Bayer HealthCare AG, Bayer Pharma AG, and Bayer AG. To read more, click Levin Law NewsXarelto Users: The Hidden Costs You Pay:
Ned McWilliams, lead attorney for Levin, Papantonio’s lawsuit against the makers of the drug Xarelto, lays out the real-life costs that users of Xarelto and their families pay every day. To read more, click Levin Law NewsDid The Makers of Xarelto Put Marketing Potential Above Potential Health?:
I, like most people, tend to want to believe that the advancements in prescription drugs which have enabled us, in general, to live longer, healthier lives, along with our own regulatory bodies, namely the United States Food and Drug Administration, mean that the drugs that should help us – the drugs our doctors prescribe – are doing exactly that. Helping. To read more, click Ring of Fire Radio NewsXarelto Lawyer Ned McWilliams on The Implications of FDA Xarelto Decisions for Users:
Levin, Papantonio attorney Ned McWilliams answers client questions regarding Xarelto and the Xarelto lawsuit he recently filed against the drug’s manufacturer Janssen Pharmaceutical (a subsidiary of Johnson & Johnson) and its co-marketer Bayer Healthcare AG. To read more, click LevinLaw NewsXarelto Here We Go Again:
In recent years, various players in the pharmaceutical industry have introduced a new line of anticoagulant drugs (popularly known as “blood thinners,” although this is not quite accurate – read on) that have promised to make life much easier for physicians who treat patients at risk for stroke. A stroke of course is the result of a blood clot that cuts off blood supply to the brain, and can result in permanent injury and even death. To read more, click LevinLaw News